GH Research PLC (NASDAQ:GHRS) Sees Large Increase in Short Interest

GH Research PLC (NASDAQ:GHRS) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,280,000 shares, an increase of 11.8% from the December 15th total of 2,040,000 shares. Based on an average daily volume of 72,900 shares, the days-to-cover ratio is currently 31.3 days. Currently, 7.5% of the shares of the company are short sold.

Wall Street Analyst Weigh In

GHRS has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of GH Research in a research report on Friday, January 10th. Canaccord Genuity Group lowered their price target on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP boosted its position in GH Research PLC (NASDAQ:GHRS) by 19.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the period. GH Research comprises approximately 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd largest position. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Stock Up 3.3 %

NASDAQ:GHRS traded up $0.28 during midday trading on Friday, reaching $8.88. The stock had a trading volume of 61,082 shares, compared to its average volume of 78,587. The stock has a market cap of $462.01 million, a P/E ratio of -11.24 and a beta of 0.84. The firm has a fifty day simple moving average of $8.45 and a two-hundred day simple moving average of $9.07. GH Research has a 12-month low of $5.50 and a 12-month high of $14.99.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).